| __timestamp | ADMA Biologics, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 55305000 |
| Thursday, January 1, 2015 | 7015946 | 77593000 |
| Friday, January 1, 2016 | 7688238 | 50013000 |
| Sunday, January 1, 2017 | 6229587 | 58914000 |
| Monday, January 1, 2018 | 3926120 | 65927000 |
| Tuesday, January 1, 2019 | 2343848 | 59815000 |
| Wednesday, January 1, 2020 | 5907013 | 56188000 |
| Friday, January 1, 2021 | 3646060 | 53012000 |
| Saturday, January 1, 2022 | 3613764 | 32815000 |
| Sunday, January 1, 2023 | 3300000 | 27189000 |
| Monday, January 1, 2024 | 25353000 |
Infusing magic into the data realm
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, ADMA Biologics, Inc. and Mesoblast Limited have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Mesoblast consistently outspent ADMA, with its R&D expenses peaking at nearly 78 million in 2015, a staggering 40% higher than ADMA's highest expenditure in 2014. However, both companies have shown a downward trend in recent years, with Mesoblast's R&D budget decreasing by approximately 51% from 2015 to 2023. Meanwhile, ADMA's spending has seen a more modest decline of around 65% from its peak. This data highlights the dynamic nature of R&D investment strategies in the biotech sector, reflecting broader industry trends and economic pressures.
Comparing Innovation Spending: Merck & Co., Inc. and ADMA Biologics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ADMA Biologics, Inc.
R&D Insights: How Bio-Techne Corporation and ADMA Biologics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Blueprint Medicines Corporation and Mesoblast Limited
Research and Development: Comparing Key Metrics for TG Therapeutics, Inc. and ADMA Biologics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Viridian Therapeutics, Inc.
Analyzing R&D Budgets: Amicus Therapeutics, Inc. vs Mesoblast Limited
Who Prioritizes Innovation? R&D Spending Compared for ImmunityBio, Inc. and Mesoblast Limited
Research and Development Investment: Mesoblast Limited vs MannKind Corporation
R&D Insights: How Mesoblast Limited and Celldex Therapeutics, Inc. Allocate Funds